- My Forums
- Tiger Rant
- LSU Recruiting
- SEC Rant
- Saints Talk
- Pelicans Talk
- More Sports Board
- Winter Olympics
- Fantasy Sports
- Golf Board
- Soccer Board
- O-T Lounge
- Tech Board
- Home/Garden Board
- Outdoor Board
- Health/Fitness Board
- Movie/TV Board
- Book Board
- Music Board
- Political Talk
- Money Talk
- Fark Board
- Gaming Board
- Travel Board
- Food/Drink Board
- Ticket Exchange
- TD Help Board
Customize My Forums- View All Forums
- Show Left Links
- Topic Sort Options
- Trending Topics
- Recent Topics
- Active Topics
Started By
Message
re: AUPH - Aurinia Pharmaceuticals
Posted on 3/15/22 at 7:01 am to bayoubengals88
Posted on 3/15/22 at 7:01 am to bayoubengals88
8s would be absurd. I bought another 1000 shares yesterday. I'd assume we see a bounce back to high 10s before 8s. Will try to flip and collect more shares
1
Posted on 3/15/22 at 11:47 am to jimjackandjose
Serious frickery today
Posted on 3/17/22 at 9:29 am to LChama
Anyone see this?
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100k to Contact the Firm
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100k to Contact the Firm
quote:
March 16, 2022 10:59 AM Eastern Daylight Time
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aurinia Pharmaceuticals Inc. (“Aurinia” or “the Company”) (NASDAQ: AUPH) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Aurinia announced its financial results for the quarter and full year ending December 31, 2021, with a press release issued on February 28, 2022. The Company reported a year-over-year revenue decline, and a weak sales outlook for 2022. Based on this news, shares of Aurinia dropped by 24% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Contacts
The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com
Posted on 3/17/22 at 9:31 am to Sgt_Lincoln_Osiris
quote:
Anyone see this?
Nothingburger
Posted on 3/17/22 at 9:57 am to bayoubengals88
This will end being a big lesson for me. I backed the truck up even more so close to the 30’s. I had never seen something seem more sure.
I had no idea that management would purposefully tank the share price to enrich themselves with options and shares.
I guess this is part of learning the game. Stings a bit though but I’m confident in the value of the drug. It’s ironic I find conviction in the fundamentals of a stock only to be trashed by the company’s management itself.
I’ll hold since I got 30 years but hopefully I’ll remember this.
I had no idea that management would purposefully tank the share price to enrich themselves with options and shares.
I guess this is part of learning the game. Stings a bit though but I’m confident in the value of the drug. It’s ironic I find conviction in the fundamentals of a stock only to be trashed by the company’s management itself.
I’ll hold since I got 30 years but hopefully I’ll remember this.
Posted on 3/17/22 at 10:09 am to CorkRockingham
I just bought a bit more in the 11s. If you've got a decent amount around 30, this is an opportunity to bring your cost basis down big time. Assuming of course you still believe in the stock. Median 12 month target is $28.
Posted on 3/17/22 at 10:10 am to CorkRockingham
I'm certainly not as experienced as most here, but these biotechs have ALL taught me one thing..
When public confidence is at or near 100%, be worried.
When things look their most bleak (assuming it's not just dead and going bankrupt), that's your entry.
When public confidence is at or near 100%, be worried.
When things look their most bleak (assuming it's not just dead and going bankrupt), that's your entry.
Posted on 3/17/22 at 10:41 am to jmcwhrter
I wouldn't it look at it as that black and white, especially in biotech. A lot of times a stock will rise in anticipation of an approval for one of their pipeline products. If it gets rejected and they don't have much else coming behind it, the stock will understandably tank, and I would not consider that the time to jump in.
I've talked about AXSM a bunch on here. They have two drugs they're about to hear back on. The first should be this month and the second is end of April. If both get approved, this things should get up near $70 or $80 or more per share. If only one, probably in the $50 range. Neither and we're probably talking around $10.
I've talked about AXSM a bunch on here. They have two drugs they're about to hear back on. The first should be this month and the second is end of April. If both get approved, this things should get up near $70 or $80 or more per share. If only one, probably in the $50 range. Neither and we're probably talking around $10.
This post was edited on 3/17/22 at 10:42 am
Posted on 3/17/22 at 11:01 am to jmcwhrter
It's trading in the low $30s. You can still get in before the FDA response comes back. My spidey senses are telling me it's gonna be this month on AXS-05. It was $50 right up until the FDA missed their PDUFA date and talks continued. So approval would put it above that price point. And as I noted, AXS-07 in migraine is gonna hear back at the end of next month.
This post was edited on 3/17/22 at 11:03 am
Posted on 3/18/22 at 7:38 am to bayoubengals88
Why doesn’t total prescriptions continue steadily upward? Unless I don’t understand how they are counted this should have hundreds of total prescriptions from selling all last year through now right?
Posted on 3/18/22 at 7:41 am to CorkRockingham
It is very expensive and doctors are owned by pharmaceutical companies. Auph is not a pharmaceutical company yet.
Most doctors probably don’t know this shite exist
Most doctors probably don’t know this shite exist
Posted on 3/18/22 at 8:08 am to jimjackandjose
11 new scripts this week.. two weeks in a row above 10
They're picking up some steam but March is almost over.. so I'm guessing Peter will be right and Q1 sales will be putrid
They're picking up some steam but March is almost over.. so I'm guessing Peter will be right and Q1 sales will be putrid
Posted on 3/18/22 at 9:17 am to jimjackandjose
quote:
doctors are owned by pharmaceutical companies.
What do you mean by this and how does it relate to sales in this case?
Posted on 3/18/22 at 9:26 am to jmcwhrter
quote:You're kidding right? He manipulated the hell out of it by saying "agressive" then going really conservative, and now we should easily beat guidance.
so I'm guessing Peter will be right and Q1 sales will be putrid
Already at 140 total scripts compared to 119 for Q4.
This post was edited on 3/18/22 at 9:27 am
Posted on 3/18/22 at 10:38 am to bayoubengals88
I'm confused... everything about that chart you posted shows considerable slowing
ETA: I guess I see what you're getting at.. Even if it's slowing, with more total Rx the revenue should be higher in Q1 than Q4-21
ETA: I guess I see what you're getting at.. Even if it's slowing, with more total Rx the revenue should be higher in Q1 than Q4-21
This post was edited on 3/18/22 at 10:44 am
Posted on 3/18/22 at 11:11 am to jmcwhrter
quote:Yeah that's pretty much my perspective.
ETA: I guess I see what you're getting at.. Even if it's slowing, with more total Rx the revenue should be higher in Q1 than Q4-21
The way Peter was talking on the earnings call, it really seemed that Q1 would fail to even meet Q4 revenue. Or, best case scenario would be 25 million.
However, it looks like we could see 170 scripts from Bloomberg, which makes me think guidance will be top end of the 135 range plus mileston payment.
I was thinking Q1 would be abysmal, but the numbers do not indicate that.
I did not downvote you
Posted on 3/18/22 at 11:25 am to bayoubengals88
quote:
I was thinking Q1 would be abysmal, but the numbers do not indicate that.
For good reason. You (and the larger market) were intentionally misled so they could distribute and buy more shares to the management at the expense of the rest of us.
As you pointed out progress on sales is actually pretty reasonable. The data on safety and efficacy are all we could have hoped for six months ago
Posted on 3/18/22 at 11:28 am to Chucktown_Badger
quote:
doctors are owned by pharmaceutical companies.
What do you mean by this and how does it relate to sales in this case?
My guess is he references the tendency of pharmaceutical companies to wine and dine (or bribe) general practitioners to increase their willingness to write more prescriptions.
Posted on 3/18/22 at 12:06 pm to bayoubengals88
Curious, what is RRx?
Page 132 of 167
Popular
Back to top
Follow TigerDroppings for LSU Football News